Synlogic, Inc. financial data

Symbol
SYBX on Nasdaq
Industry
Pharmaceutical Preparations
Location
Po Box 30, Winchester, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Mirna Therapeutics, Inc. (to 8/25/2017)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 313 % -53.4%
Return On Equity -195 % -129%
Return On Assets -113 % -77.6%
Operating Margin -1.95K % +71.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.7M shares -83%
Common Stock, Shares, Outstanding 11.7M shares -83%
Common Stock, Value, Issued 12K USD -83.6%
Weighted Average Number of Shares Outstanding, Basic 12.2M shares +161%
Weighted Average Number of Shares Outstanding, Diluted 12.4M shares +165%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.17M USD +219%
Research and Development Expense 29.6M USD -43.5%
General and Administrative Expense 10.7M USD -33.2%
Operating Income (Loss) -61.7M USD +8.65%
Nonoperating Income (Expense) 5.54M USD +144%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.02M USD
Income Tax Expense (Benefit) 5K USD -44.4%
Net Income (Loss) Attributable to Parent -56.2M USD +14%
Earnings Per Share, Basic -4.65 USD/shares +76.7%
Earnings Per Share, Diluted -4.65 USD/shares +76.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20M USD -56.8%
Cash, Cash Equivalents, and Short-term Investments 20M USD -56.8%
Other Assets, Current 353K USD
Assets, Current 21.6M USD -56.5%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 12K USD -25%
Assets 21.6M USD -72.7%
Accounts Payable, Current 126K USD -88.4%
Employee-related Liabilities, Current 14K USD -99.4%
Accrued Liabilities, Current 2.3M USD -35.2%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 5.65M USD -41.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -444M USD -14.5%
Stockholders' Equity Attributable to Parent 16M USD -70.8%
Liabilities and Equity 21.6M USD -72.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.4M USD +28.2%
Net Cash Provided by (Used in) Financing Activities 16K USD -98.2%
Net Cash Provided by (Used in) Investing Activities 16.3M USD -46.2%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 12M shares -83.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 862K USD -91.1%
Deferred Tax Assets, Valuation Allowance 125M USD +14.1%
Deferred Tax Assets, Gross 128M USD +13.1%
Operating Lease, Liability 17.3M USD -14.8%
Depreciation 347K USD -39.8%
Payments to Acquire Property, Plant, and Equipment 395K USD +176%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.2M USD +13.4%
Lessee, Operating Lease, Liability, to be Paid 20.4M USD -17.8%
Property, Plant and Equipment, Gross 19.9M USD -2.82%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.79M USD -20.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.98M USD +6.24%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.09M USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.91M USD +2.98%
Deferred Tax Assets, Operating Loss Carryforwards 87.4M USD +6.84%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.02M USD +3%
Share-based Payment Arrangement, Expense 4.16M USD +32.8%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares